Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Quantitative strength testing in ALS clinical trials.

Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M.

Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6.

2.

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML.

Neurotherapeutics. 2015 Apr;12(2):417-23. doi: 10.1007/s13311-015-0336-z. Review.

3.

Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, Li G, Fang L, Mackey L, Hardiman O, Cudkowicz M, Sherman A, Ertaylan G, Grosse-Wentrup M, Hothorn T, van Ligtenberg J, Macke JH, Meyer T, Schölkopf B, Tran L, Vaughan R, Stolovitzky G, Leitner ML.

Nat Biotechnol. 2015 Jan;33(1):51-7. doi: 10.1038/nbt.3051. Epub 2014 Nov 2.

PMID:
25362243
4.

Infrastructure resources for clinical research in amyotrophic lateral sclerosis.

Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, Harris BT, Horton DK, Kaufmann P, Leitner ML, Miller R, Shefner J, Vonsattel JP, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:53-61. doi: 10.3109/21678421.2013.779058. Review.

PMID:
23678880
5.

Expression and function of GDNF family ligands and receptors in the carotid body.

Leitner ML, Wang LH, Osborne PA, Golden JP, Milbrandt J, Johnson EM Jr.

Exp Neurol. 2005 Feb;191 Suppl 1:S68-79.

PMID:
15629763

Supplemental Content

Loading ...
Support Center